PUMA BIOTECHNOLOGY, INC. Uncategorized Contracts & Agreements
16 Contracts & Agreements
- Open Market Sale AgreementSM, dated November 4, 2021, by and between Puma Biotechnology, Inc. and Jefferies LLC (Filed With SEC on November 4, 2021)
- Letter Agreement, dated February 13, 2020, by and between the Company and Jeff J. Ludwig (Filed With SEC on March 1, 2021)
- Pfizer Letter Agreement dated June 8, 2020, by and between the Company and Pfizer Inc (Filed With SEC on August 6, 2020)
- Description of the Company's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 (Filed With SEC on February 28, 2020)
- Side Letter Agreement, dated November 19, 2018, between the Company and CANbridge Biomed Limited (as successor in interest to CANbridgepharma Limited) (Filed With SEC on March 1, 2019)
- Letter Agreement, dated December 8, 2017, between the Company and Douglas Hunt (Filed With SEC on March 9, 2018)
- 10880 Wilshire Blvd. Suite 2150 Los Angeles, CA 90024 424.248.6500 Phone 424.248.6501 Fax (Filed With SEC on August 9, 2016)
- 10880 Wilshire Blvd. Suite 2150 Los Angeles, CA 90024 424.248.6500 Phone 424.248.6501 Fax (Filed With SEC on August 9, 2016)
- FOURTH AMENDMENT (Filed With SEC on November 9, 2015)
- 10880 Wilshire Blvd. Suite 2150 Los Angeles, CA 90024 424.248.6500 Phone 424.248.6501 Fax (Filed With SEC on November 9, 2015)
- THIRD AMENDMENT (Filed With SEC on March 2, 2015)
- SECOND AMENDMENT (Filed With SEC on March 3, 2014)
- FIRST AMENDMENT (Filed With SEC on April 1, 2013)
- 10880 Wilshire Blvd. Suite 2150 Los Angeles,California 90024 424.248.6500 Phone 424.248-6501 Fax (Filed With SEC on June 26, 2012)
- REDEMPTION AGREEMENT (Filed With SEC on October 11, 2011)
- INDEMNITY AGREEMENT (Filed With SEC on October 4, 2011)
